Defendant Name: Nano-x Imaging Ltd.

Defendant Type: Public Company

Document Reference: LR-25876

Document Details

Legal Case Name SEC v. Nano-x Imaging Ltd. and Ran Poliakine
Document Name SEC Charges Diagnostic Imaging Company and Its Former CEO for Misrepresenting the Manufacturing Costs of Its Flagship Device
Document Date 29-Sep-2023
Document Format Civil Proceeding
Case Number 23-cv-08611
Federal District Court New York, Southern District of New York
Allegation Type Issuer Reporting and Disclosure
Document Summary On September 29, 2023, the SEC "announced charges against an Israel-based diagnostic imaging company, Nano-X Imaging Ltd. (“Nanox”), and its former CEO, Ran Poliakine (“Poliakine”), for negligently misrepresenting the cost to manufacture the company’s flagship imaging device, the Nanox.ARC. Nanox and Poliakine have agreed to settle the SEC’s charges."

Disgorgement & Penalty Information

Resolutions
Injunction
Monetary Penalties:

Civil Penalty

Individual:     $650,000.00 Shared:    

Related Documents:

comp25876 29-Sep-2023 Complaint
Complaint
The SEC alleged "From August 2020 through May 2021, Nanox, an Israel-based medical imaging company, and Poliakine, its founder and then CEO, negligently made a series of false and misleading statements to investors about the estimated cost to manufacture at least 15,000 units of its flagship product, the Nanox.ARC - a device the company is developing that it claimed would make diagnostic imaging substantially more affordable than currently available medical imaging systems and accessible to patients around the globe."

Other Defendants in Action:

Ran Poliakine